MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MeiraGTx Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.45+0.17 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
MeiraGTx Holdings plc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License revenue | $74.99M | – | – | – | – | – | – | – | – | 92.1% | – |
| Service revenue - related party | $6.40M | $33.28M | – | – | – | – | – | – | – | 7.9% | -80.8% |
By region
From the segment and revenue-disaggregation notes of MeiraGTx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.